BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37539594)

  • 1. Mortality and complications in Omani patients with beta-thalassemia major: a long-term follow-up study.
    Daar S; Al-Naamani K; De Sanctis V; Al Rahbi S; Al Zadjali S; Khan H; Panjwani V; Al-Khabori M
    Acta Biomed; 2023 Aug; 94(4):e2023191. PubMed ID: 37539594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. History of myocardial iron loading is a strong risk factor for diabetes mellitus and hypogonadism in adults with β thalassemia major.
    Ang AL; Tzoulis P; Prescott E; Davis BA; Barnard M; Shah FT
    Eur J Haematol; 2014 Mar; 92(3):229-36. PubMed ID: 24164584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal study of ICET-A on glucose tolerance, insulin sensitivity and β-cell secretion in eleven β-thalassemia major patients with mild iron overload.
    De Sanctis V; Soliman AT; Daar S; Tzoulis P; Di Maio S; Kattamis C
    Acta Biomed; 2023 Feb; 94(1):e2023011. PubMed ID: 36786253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment.
    Chirico V; Rigoli L; Lacquaniti A; Salpietro V; Piraino B; Amorini M; Salpietro C; Arrigo T
    Eur J Haematol; 2015 May; 94(5):404-12. PubMed ID: 25200112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of iron overload complications among patients with b-thalassemia major treated at Dubai Thalassemia Centre.
    Belhoul KM; Bakir ML; Kadhim AM; Dewedar HE; Eldin MS; Alkhaja FA
    Ann Saudi Med; 2013; 33(1):18-21. PubMed ID: 23458935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
    Poggi M; Sorrentino F; Pugliese P; Smacchia MP; Daniele C; Equitani F; Terlizzi F; Guitarrini MR; Monti S; Maffei L; Losardo A; Pasin M; Toscano V
    Ann Hematol; 2016 Apr; 95(5):757-63. PubMed ID: 26957357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.
    Casale M; Citarella S; Filosa A; De Michele E; Palmieri F; Ragozzino A; Amendola G; Pugliese U; Tartaglione I; Della Rocca F; Cinque P; Nobili B; Perrotta S
    Am J Hematol; 2014 Dec; 89(12):1102-6. PubMed ID: 25197009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors associated with hypogonadism in β-thalassemia major patients: predictors for a frequent complication of a rare disease.
    Albu A; Barbu CG; Antonie L; Vladareanu F; Fica S
    Postgrad Med; 2014 Sep; 126(5):121-7. PubMed ID: 25295656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of iron overload and oxidative stress with insulin resistance in transfusion-dependent beta-thalassemia major and beta-thalassemia/HbE patients.
    Tangvarasittichai S; Pimanprom A; Choowet A; Tangvarasittichai O
    Clin Lab; 2013; 59(7-8):861-8. PubMed ID: 24133917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mild subclinical hypothyroidism in thalassaemia major: prevalence, multigated radionuclide test, clinical and laboratory long-term follow-up study.
    De Sanctis V; De Sanctis E; Ricchieri P; Gubellini E; Gilli G; Gamberini MR
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():174-80. PubMed ID: 19337174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of genotype on endocrine complications in thalassaemia major.
    Skordis N; Michaelidou M; Savva SC; Ioannou Y; Rousounides A; Kleanthous M; Skordos G; Christou S
    Eur J Haematol; 2006 Aug; 77(2):150-6. PubMed ID: 16800840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective study on long-term effects of hormone replacement therapy (HRT) and iron chelation therapy on glucose homeostasis and insulin secretion in female ß- thalassemia major (β-TM) patients with acquired hypogonadotropic- hypogonadism (AHH).
    De Sanctis V; Daar S; Soliman A; Tzoulis P; Di Maio S; Kattamis C
    Acta Biomed; 2023 Aug; 94(4):e2023195. PubMed ID: 37539597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
    Gamberini MR; De Sanctis V; Gilli G
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():158-69. PubMed ID: 19337172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major.
    Telfer PT; Prestcott E; Holden S; Walker M; Hoffbrand AV; Wonke B
    Br J Haematol; 2000 Sep; 110(4):971-7. PubMed ID: 11054091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complications and treatment of patients with β-thalassemia in France: results of the National Registry.
    Thuret I; Pondarré C; Loundou A; Steschenko D; Girot R; Bachir D; Rose C; Barlogis V; Donadieu J; de Montalembert M; Hagege I; Pegourie B; Berger C; Micheau M; Bernaudin F; Leblanc T; Lutz L; Galactéros F; Siméoni MC; Badens C
    Haematologica; 2010 May; 95(5):724-9. PubMed ID: 20007138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha- and Beta-thalassemia: Rapid Evidence Review.
    Baird DC; Batten SH; Sparks SK
    Am Fam Physician; 2022 Mar; 105(3):272-280. PubMed ID: 35289581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadal dysfunction in adult male patients with thalassemia major: an update for clinicians caring for thalassemia.
    De Sanctis V; Soliman AT; Elsedfy H; Di Maio S; Canatan D; Soliman N; Karimi M; Kattamis C
    Expert Rev Hematol; 2017 Dec; 10(12):1095-1106. PubMed ID: 29072100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine complications in patients with Thalassaemia Major.
    Toumba M; Sergis A; Kanaris C; Skordis N
    Pediatr Endocrinol Rev; 2007 Dec; 5(2):642-8. PubMed ID: 18084158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival and complications in thalassemia.
    Borgna-Pignatti C; Cappellini MD; De Stefano P; Del Vecchio GC; Forni GL; Gamberini MR; Ghilardi R; Origa R; Piga A; Romeo MA; Zhao H; Cnaan A
    Ann N Y Acad Sci; 2005; 1054():40-7. PubMed ID: 16339650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
    Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
    Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.